Navigation Links
The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
Date:12/11/2013

BURLINGTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of numerous add-on therapies in the acute coronary syndrome (ACS) 12-month posthospital setting will result in market growth from $1.7 billion in 2012 to nearly $2.4 billion in 2022. A number of agents are in development for the secondary prevention of ACS events but particular excitement has been brewing around novel lipid modifying therapies. The cholesteryl ester transfer protein (CETP) inhibitors and the protein convertase substilisin/kexin type 9 (PCSK9) inhibitors are among the most anticipated therapies expected to launch for ACS and are predicted to collectively capture over a quarter of the 12-month posthospital market in 2022.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

While there will be growth in the posthospital setting, the Pharmacor advisory service entitled Acute Coronary Syndrome finds that there will be a decrease in ACS drug sales in the acute hospital market between 2012 and 2022. Despite the launch of two new intravenous agents, The Medicines Company's cangrelor and Regado Biosciences' REG-1, generic erosion of key brands such The Medicine's Company's Angiomax will lead to a contraction in this market between now and 2022.

The report also finds that the dynamics of ADP receptor antagonist use are likely to change over the next 10 years. While clopidogrel (Bristol-Myers Squibb/Sanofi's Plavix/Iscover, generics) currently dominates the acute and posthospital settings as the patient share leader, AstraZeneca's ticagrelor is set to obtain a sizeable portion of the ACS population.  

"The 12-month posthospital setting represents the most lucrative segment of the ACS market," said Decision Resources Analyst Joseph Dwyer, Ph.D. "There is a healthy pipeline of novel agents that aim to reduce cardiovascular events through different strategies and diverse mechanisms. While novel antithrombotic therapies will have trouble gaining patient share because of fears of excess bleeding, the emerging anti-dyslipidemic agents, like the CETP inhibitors and the PCSK9 inhibitors, could experience more generous uptake."  

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
4. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
5. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
6. Vibra Healthcare Announces Agreement To Manage Two Acute Rehabilitation Hospitals
7. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
8. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
9. Significant Pre-Clinical Data in Acute Lung Injury
10. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
11. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2019)... ... June 19, 2019 , ... ... in vitro toxicology testing solutions, announced the addition of the Human MDR-1 ... existing in vitro toxicology offerings and allows researchers to perform critical toxicology testing ...
(Date:6/18/2019)... , ... June 18, 2019 , ... ... new facilities at 11500 W Olympic Blvd Suite 350 Los Angeles, CA, 90064, ... through research-backed methodologies. , MY Education Guru has created individual programs to ...
(Date:6/18/2019)... Tenn. (PRWEB) , ... June 18, 2019 , ... ... leader in emergency medicine and hospital medicine management services, are pleased to announce ... company based in Longview, Texas. , LEMA’s 34 physicians and 9 advanced ...
Breaking Medicine Technology:
(Date:6/19/2019)... ... ... CEO Steven C. Bilt of Smile Brands Inc. has won a Glassdoor Employees’ ... one of the world’s largest job and recruiting sites, released its annual report recognizing ... North America and parts of Europe. , Smile Brands, a leading dental support organization ...
(Date:6/19/2019)... ... June 19, 2019 , ... LifeLearn Animal Health launches ... pet insurance is, what it isn’t, and the questions they need to ask prior ... from different pet insurance companies and find the coverage that meets their budget and ...
(Date:6/18/2019)... ... June 18, 2019 , ... NeoTract, a wholly owned subsidiary ... urology, today announced that Aaron Berger, MD, Associated Urological Specialists, LLC in Chicago ... that Dr. Aaron Berger has achieved a high level of training and experience ...
(Date:6/16/2019)... ... June 16, 2019 , ... Ted Danson on CNBC ... research for the advancement of medical marijuana-based pharmaceuticals in an upcoming episode, scheduled ... more information. , With two investigational new drug applications already accepted by the ...
(Date:6/13/2019)... ... June 13, 2019 , ... MMJ BioPharma Cultivation, ... signed a memorandum of understanding (MOU) with MMJ International Holdings to grow cannabis ... , MMJ BioPharma Cultivation will be supplying MMJIH with extracts from the marijuana ...
Breaking Medicine News(10 mins):